Phase 4 N=54 Randomized Single-blind Other

Ketamine vs Hydromorphone

Laparoscopic Gastric Bypass · Obesity · Pain, Postoperative

Bottom Line

View on ClinicalTrials.gov: NCT03001843 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcome: Primary: Pain Measured Based on Pain Medication Used on a Scale of 0-10 — 1.3; 0.7 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Ketamine (Drug); Narcotics (Drug); pain scale (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Florida
Primary completion: Dec 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Pain Measured Based on Pain Medication Used on a Scale of 0-10	1.3; 0.7	—
SECONDARY Length of Stay (Hours)	43.6; 39.8	—

Summary

This study will help to determine if investigators can minimize narcotic use in laparoscopic gastric bypass patients while maintaining adequate pain control. This will allow investigators to minimize the negative side effects of narcotics which is a goal in this population.

Eligibility Criteria

Inclusion Criteria

Obese patient presenting for laparoscopic gastric bypass between 18 and 65 years of age

Exclusion Criteria

Hypersensitivity, allergy, or contraindications to fentanyl, propofol, or ketamine.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03001843). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.